Functional constipation (FC) is a common pediatric problem accounting for 3 % visits to a general pediatrician and up to 25 % visits to a pediatric gastroenterologist. Presence of FC significantly impacts a child’s health‑related quality of life and the healthcare cost burden. The North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition Guideline (NASPGHAN) recommends supportive treatment with laxatives, training, recommendations on fiber and fluid intake, and physical activity in constipation in children. Modern pharmacological treatments may be ineffective in some patients — not optimal dosage, poor compliance or use of drugs with mechanisms of action that do not affect the main pathophysiological moments. Many patients with constipation report dissatisfaction with traditional treatments due to perceived lack of efficacy. Objective — to study the effectiveness of the prebiotic Inulin Neo for pediatric patients with functional constipation aged 3 to 18 years. Materials and methods. Observation involved 48 children aged 3 to 18 years with a diagnosis of functional constipation. Patients were divided into two groups. The main group consisted of 29 children who received the prebiotic Inulin Neo. The control group included 19 children who did not receive prebiotic. Results. After 30 days of treatment, children of the main group vs control group demonstrated significantly better positive dynamics of the following indices: relief of abdominal pain and pain during defecation, decrease in colic and bloating, normalized frequency of defecation and consistency of stools, increased bifidoflora amount and normalized coprological indicators. The results suggest effectiveness of Inulin Neo and feasibility of its inclusion into the treatment of functional constipation in children. Conclusions. Symptoms of functional constipation significantly decreased or disappeared in children who received Inulin Neo, most of the indices of microbiocenosis and coprological investigations considerably improved, whereas pediatric patients of the control group demonstrated only the trend to their improvement. No intolerability signs or adverse events during Inulin Neo administration have been revealed.